MedTrace Logo

Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma

NCT00656812 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-12-24

No results posted yet for this study

Summary

The purpose of this trial is to evaluate whether a Rituximab plus 2 CdA combination therapy is effective and safe in the treatment of patients with advanced or relapsed lymphoma of the mucosa associated lymphoid tissue (MALT).

Conditions

  • Lymphoma of Mucosa-Associated Lymphoid Tissue

Interventions

DRUG

Rituximab

375 mg/m2 on day 1 of a 21-day treatment cycle

DRUG

2-CdA

0.1 mg/kg s.c. on days 1 - 4 of a 21-day treatment cycle

Sponsors & Collaborators

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Lipomed

    collaborator INDUSTRY

  • Arbeitsgemeinschaft medikamentoese Tumortherapie

    lead OTHER

Principal Investigators

  • Markus Raderer, Prof. Dr. · AKH Wien / Universitaetsklinik fuer Innere Medizin I

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00656812 on ClinicalTrials.gov